Serotiny is a pre-clinical discovery company building better CAR T-Cell therapies through engineering novel Chimeric Antigen Receptors (CARs), alternative CARs and accessory proteins in high-throughput. At the heart of Serotiny’s technology is a discovery platform involving the close interworking of computationally aided protein design, high-throughput cellular assays, and next generation sequencing, which enables Serotiny to engineer multi-domain proteins for cell therapies, like Chimeric Antigen Receptors used in CAR-T immunotherapies. Rationally designing proteins for cell-therapies requires a different set of constraints and design tools than enzyme or antibody engineering. Serotiny encodes these constraints into its platform to create a scaled design-build-test-learn process.